Combined immunodeficiency due to MALT1 deficiency is a rare genetic disease where the immune system does not work properly because a gene called MALT1 is damaged in both copies. This gene normally helps infection-fighting white blood cells (T cells and B cells) turn on important “danger” signals inside the cell. When MALT1 does not work, these cells cannot switch on well, so the body cannot fight germs in a normal way. Children usually become sick early in life with many infections, stomach problems, skin rashes, and poor growth.
Combined immunodeficiency due to MALT1 deficiency is a very rare, inherited immune system disease where a mistake (mutation) in the MALT1 gene stops immune cells from working properly. MALT1 is an important part of the “CBM complex,” a tiny molecular machine that turns on NF-κB, a pathway needed for T-cell and B-cell activation. When MALT1 is missing or does not work, the body cannot make a strong immune response, so children get repeated serious infections, long-lasting inflammation of the gut and skin, poor growth, and sometimes life-threatening viral infections such as cytomegalovirus (CMV).
Doctors classify this as a combined immunodeficiency (CID) because both T-cells and B-cells are affected. Newborn screening for classic SCID can be normal, so diagnosis often needs genetic testing once severe infections, eczema, chronic diarrhoea, or poor weight gain appear. Supportive care (infection prevention, nutrition, skin and gut care) is essential from the beginning. For long-term control or cure, many experts now recommend hematopoietic stem cell transplantation (HSCT) in specialized centres, because reports show HSCT can restore immune function in MALT1 deficiency.
MALT1 deficiency is classed as a combined immunodeficiency, because both T cells and B cells are affected. In many patients, the number of these cells in the blood can be close to normal, but their function is weak, especially their ability to signal through a pathway called NF-κB, which is needed to make immune responses and memory cells. This weak signaling leads to repeated infections, chronic inflammation in the gut and lungs, and sometimes problems like autoimmunity (the immune system attacking the body itself).
Other names
Doctors and researchers may use different names for the same condition. All of the names below describe the same disease or very closely related descriptions:
-
Combined immunodeficiency due to MALT1 deficiency – formal disease name used in rare-disease databases.
-
MALT1 deficiency – short everyday name often used in clinics and reviews.
-
MALT1-related combined immunodeficiency – used in research papers to stress that MALT1 mutations are the cause.
-
Immunodeficiency type 12 (IMD12) – an older numeric name in some genetic catalogues.
-
Inborn error of immunity due to MALT1 mutation – used in modern immunology to show it is a single-gene immune defect present from birth.
All these terms refer to the same basic problem: both copies of the MALT1 gene are not working well, so the person has a lifelong immune system weakness.
Types
Experts now think there are a few patterns or types of MALT1 deficiency based on how badly the gene is damaged and which part of the protein is affected. These types overlap, but the idea helps explain why symptoms can be mild in some people and very severe in others.
-
Type 1 – Complete loss of MALT1 protein
In this type, both copies of the MALT1 gene have strong “loss-of-function” mutations. The body makes little or no full MALT1 protein. T cells and B cells cannot send NF-κB signals properly, so infections begin very early, and symptoms are usually severe. -
Type 2 – Partial or “hypomorphic” MALT1 deficiency
Here, the gene changes still allow some MALT1 protein to be made and to work a little. NF-κB signals are weaker than normal but not totally absent. Symptoms can be milder or appear later, and some immune tests may look closer to normal, but there is still a high risk of infections and inflammation. -
Type 3 – Predominant loss of paracaspase (enzymatic) activity
MALT1 has two main jobs: it acts as a scaffold (a structure for other proteins to bind) and as an enzyme called a paracaspase. Some mutations especially damage the enzyme part but keep some scaffold function. This can give a mixed picture: clear infection risk plus strong inflammation, because immune control cells (like regulatory T cells) are also altered.
In real life, a person’s disease may not fit perfectly into a single box, but thinking in these types helps doctors match the genetic result with the clinical picture.
Causes
For this disease, the true basic cause is always the same:
a person is born with harmful mutations in both copies of the MALT1 gene, following an autosomal recessive inheritance pattern. All the “causes” below are different ways or situations in which this same problem can happen or become more likely.
-
Autosomal recessive inheritance of faulty MALT1 gene
The main cause is inheriting one faulty MALT1 gene from each parent. Each parent is usually healthy but carries one changed copy. When a child receives both changed copies, the child develops MALT1 deficiency and combined immunodeficiency. -
Homozygous nonsense (stop) mutations
Some patients have the exact same “stop” mutation on both gene copies. This type of mutation tells the cell to stop making the protein too early, so almost no working MALT1 is produced. -
Homozygous missense mutations
Other patients have the same “missense” mutation on both copies of the gene. A missense mutation changes one building block (amino acid) in the protein. This can bend MALT1 into the wrong shape so it cannot join the signaling complex or cut its normal targets. -
Splice-site mutations in MALT1
Some mutations sit at the borders of gene segments (introns and exons) and disturb RNA “splicing,” the editing step before protein is made. This can remove important pieces of MALT1 or insert extra pieces, leading to a non-working protein. -
Frameshift mutations
Small insertions or deletions in the MALT1 gene can shift the reading frame. This usually creates a nonsense sequence and an early stop, again causing loss of normal protein. -
Large deletions in the MALT1 gene
In a few cases, a bigger chunk of the gene can be missing. When important exons are deleted, the body cannot make a complete MALT1 protein, so signaling fails. -
Mutations in the paracaspase (enzyme) domain
If the change hits the enzyme part of MALT1, the protein may still be present but cannot cut its normal targets. This leads to poor activation of NF-κB and abnormal balance between effector T cells and regulatory T cells, promoting both infections and inflammation. -
Mutations in scaffold or interaction domains
Some variants mainly disturb the ability of MALT1 to bind its partners in the CARD11-BCL10-MALT1 complex (CBM). Even if the enzyme is partly active, the signal complex cannot form properly, so immune cell activation is still weak. -
Compound heterozygous mutations
In some families, each parent passes a different mutation in MALT1. The child then has two different faulty versions (compound heterozygosity). Together they still cause loss of function of the protein. -
De novo (new) MALT1 mutation in the child
Very rarely, a child can have a mutation that is not found in either parent, due to a new error in the sperm, egg, or early embryo. If the other copy also becomes non-functional (for example by a second subtle variant), the child can still develop MALT1 deficiency. -
Carrier parents from consanguineous (related) marriages
In families where parents are related by blood (for example, first cousins), they are more likely to carry the same rare mutation. This increases the chance that a child will inherit two faulty MALT1 copies. -
Family history of early severe infections or known MALT1 deficiency
If brothers, sisters, or close relatives have died in infancy or have known MALT1 deficiency or similar combined immunodeficiency, the risk for later children is higher, because the same mutation may run in the family. -
Mutations that reduce MALT1 expression (low protein levels)
Some gene changes mainly lower how much MALT1 protein is made, instead of destroying it completely. Even reduced levels can be enough to disturb signaling and cause disease. -
Mutations that destabilize the CBM complex
Changes in key contact regions can prevent MALT1 from binding CARD11 and BCL10. Even if the gene is present, the whole CBM complex becomes unstable, so NF-κB cannot switch on well after antigen stimulation. -
Mutations that particularly affect B-cell function
Some variants are linked with strong B-cell problems like progressive B-cell loss and weak antibody responses, which contribute heavily to recurrent infections. -
Mutations that particularly affect regulatory T cells
If the mutation strongly affects cells that normally calm the immune system (regulatory T cells), patients may develop autoimmunity and chronic inflammation along with infections. -
Mutations associated with high IgE and eosinophilia
Some patients show allergic-like features such as high IgE levels and increased eosinophils. This pattern comes from specific ways that MALT1 signaling is disrupted and is another form of the same genetic cause. -
Mutations that preserve cell numbers but block signaling
In many patients, lymphocyte counts and newborn SCID screening appear normal, but signaling inside the cells is blocked. The “hidden” nature of these mutations can delay diagnosis while still clearly causing disease. -
Inherited variants combined with environmental infections
In all cases the MALT1 mutations are the true cause, but exposure to common viruses, bacteria, and fungi then reveals the immune defect, because the body cannot respond normally. -
Lack of early diagnosis and treatment in affected children
Again, this is not a new genetic cause, but when an existing MALT1 mutation goes undiagnosed, repeated infections and inflammation can worsen organ damage. Early recognition of the genetic cause is therefore very important for outcome.
Symptoms
People with MALT1 deficiency can have many different symptoms. Not everyone has all of them, but the list below covers common and important features seen across reported patients.
-
Recurrent chest infections
Children often have repeated bronchitis and pneumonia. Over time this can damage the airways and cause bronchiectasis, where the air tubes become widened and scarred, leading to chronic cough and breathlessness. -
Frequent skin infections
Bacterial or viral infections of the skin, such as boils, abscesses, or herpes infections, are common because the skin immune defense is weak. -
Severe eczema or dermatitis
Many patients have long-lasting red, itchy, scaly skin rashes. The skin barrier is damaged, which both reflects immune problems and increases infection risk. -
Chronic inflammatory lung disease
Even between acute infections, inflammation in the lungs may continue, causing chronic cough, wheeze, and reduced exercise tolerance. -
Inflammatory gastrointestinal disease
The gut lining can be inflamed, leading to chronic diarrhea, abdominal pain, and sometimes blood or mucus in the stool. It may look similar to inflammatory bowel disease. -
Failure to thrive and poor growth
Many children do not gain weight or height as expected. This comes from poor absorption of food, long illnesses, and the heavy energy cost of chronic inflammation. -
Oral ulcers and severe periodontal disease
Patients often have painful mouth ulcers, gum disease, and early tooth problems, because the local immune system in the mouth is weak and chronic inflammation damages tissues. -
Meningitis or other serious invasive infections
Some patients suffer infections of the brain coverings (meningitis) or bloodstream infections (sepsis). These are medical emergencies and show how serious the immune defect is. -
Long-lasting viral infections (for example CMV)
Cytomegalovirus (CMV) and other viruses may persist, because T cells cannot fully clear them. The infection can smolder for months and cause organ damage. -
Chronic diarrhea
Beyond inflammatory bowel-type disease, some patients have long-term watery stools due to a mix of gut infection, inflammation, and poor immune control of gut microbes. -
Autoimmune problems
A subset of patients develop immune attacks on their own tissues, such as autoimmune cytopenias (low blood counts) or other autoimmune diseases, reflecting loss of immune balance. -
Allergic-like features (high IgE, eczema, asthma-like symptoms)
Some children show strong eczema, wheeze, or other atopic signs together with high IgE and eosinophilia, giving an “allergic plus infection” picture. -
Fractures and bone problems
Long bone fractures have been reported in several patients. They may be related to chronic inflammation, poor nutrition, or steroid treatment for inflammatory complications. -
Lymph node and organ enlargement
Some children show big lymph nodes or enlarged spleen or liver, as the immune system is constantly stimulated but cannot clear infections well. -
General fatigue and weakness
Ongoing infections, poor nutrition, and chronic inflammation often cause low energy, reduced school or play activity, and a general feeling of being unwell.
Diagnostic tests
Physical exam
Diagnosis always starts with careful history and physical examination by a doctor experienced in immune diseases.
Height and weight measurement
The doctor measures weight, height, and head size and plots them on growth charts. Slow or falling growth lines (failure to thrive) can suggest a chronic immune problem like MALT1 deficiency, especially when combined with frequent infections.
Skin and hair examination
The doctor looks for eczema, rashes, scars from previous infections, hair loss patches, or other skin changes. In MALT1 deficiency, they often see widespread eczema, scratch marks, infected lesions, and sometimes signs of long-term inflammation.
Chest examination with a stethoscope
Listening to the lungs can show crackles, wheezes, or reduced breath sounds. Repeated abnormal findings over time suggest recurrent or chronic lung disease such as bronchiectasis.
Oral and dental examination
The clinician inspects the mouth, gums, and teeth for ulcers, chronic redness, swelling, and tooth decay. Severe periodontal disease and frequent ulcers are important clues for MALT1 deficiency.
Manual tests
These are simple bedside tests that the doctor performs without complex machines.
Palpation of lymph nodes and spleen
The doctor uses their hands to feel for enlarged lymph nodes in the neck, armpits, and groin, and to check the size of the liver and spleen in the abdomen. Large nodes or an enlarged spleen can reflect chronic immune activation or infection.
Manual chest percussion
By gently tapping on the chest wall and listening to the sound, the doctor can detect areas of fluid or over-inflation. Dull sounds may suggest pneumonia or other lung changes needing imaging.
Six-minute walk test
In older children, walking for six minutes while measuring distance and monitoring breathing can show how much the lungs are affected. Poor performance or early breathlessness may point to chronic lung involvement.
Lab and pathological tests
Lab tests are the core of diagnosing primary immunodeficiencies such as MALT1 deficiency.
Complete blood count (CBC) with differential
This test counts red cells, platelets, and different white cells. In MALT1 deficiency, total lymphocyte numbers can be normal, but there may be anemia, low platelets, eosinophilia, or other changes that support an immune problem and help exclude other diseases.
Lymphocyte subset analysis (flow cytometry)
Special markers on white cells are measured to see how many T cells, B cells, and NK cells are present. In MALT1 deficiency, counts may look normal, but detailed analysis often shows abnormalities in memory cells or regulatory T cells.
Serum immunoglobulin levels (IgG, IgA, IgM, IgE)
Levels of antibodies are checked. In some patients these are near normal; in others they may be low or abnormal, and IgE can be high. This pattern helps distinguish MALT1 deficiency from other immunodeficiencies.
Specific antibody responses to vaccines
Doctors measure antibodies to vaccines such as tetanus or pneumococcus. Poor response despite vaccination shows that B cells are not functioning well, which supports a diagnosis of combined immunodeficiency.
Lymphocyte proliferation assays
T cells are taken from the blood and stimulated in the lab with specific chemicals or antibodies. In MALT1 deficiency, these cells often show poor proliferation and weak cytokine production, reflecting impaired NF-κB signaling.
Functional tests of B-cell activity
Some centers study B-cell responses in more detail, including class-switching and memory B-cell formation. Many patients with MALT1 deficiency show progressive B-cell problems over time.
Stool and blood cultures or PCR tests for pathogens
Because patients have repeated infections, doctors often send stool, blood, and other samples to look for bacteria, viruses, and parasites. Finding unusual or repeated organisms supports the suspicion of an underlying immune defect.
TREC newborn screening (when available)
Most infants with MALT1 deficiency have normal T-cell receptor excision circle (TREC) newborn screens, which is unusual for severe combined immunodeficiency. A normal screen plus later severe infections can therefore be a clue to signaling-type defects like MALT1 deficiency.
Tissue biopsy (skin or gut)
When skin or gut inflammation is severe, a small piece of tissue may be taken and examined under the microscope. Biopsy often shows chronic inflammation and sometimes features that resemble other immune dysregulation disorders, helping narrow the diagnosis.
Bone marrow examination
In unclear cases, bone marrow may be examined to exclude malignancy or other bone-marrow failure syndromes. In MALT1 deficiency, marrow may show reactive changes but usually no primary cancer, supporting the diagnosis of an inborn immunodeficiency instead.
Genetic testing focused on the MALT1 gene
Definite diagnosis requires finding disease-causing variants in both copies of the MALT1 gene. This is done by targeted gene testing or by using larger gene panels or whole-exome sequencing that include MALT1.
Electrodiagnostic tests
Electrodiagnostic tests are not routine for MALT1 deficiency itself, but they may be used when complications suggest nervous system involvement.
Electroencephalogram (EEG)
If a patient has seizures, suspected meningitis, or other brain problems, an EEG can record electrical activity in the brain. It does not diagnose MALT1 deficiency directly, but it helps to assess and manage serious neurological complications of infections that occur because of the immune defect.
Imaging tests
Imaging helps doctors see organ damage caused by long-term infections and inflammation.
Chest X-ray
A simple chest X-ray is often the first imaging test. It can show pneumonia, lung scarring, or enlarged heart and mediastinum. Repeated abnormal X-rays in a child with recurrent chest infections strongly suggest an underlying immune problem.
High-resolution CT scan of the chest
CT scanning gives a much more detailed picture of the lungs and airways. In MALT1 deficiency it often shows bronchiectasis, small-airway disease, or areas of chronic infection. Discovering such changes early is important, because it affects long-term treatment and prognosis.
Abdominal ultrasound or CT
Ultrasound of the abdomen can show enlarged liver or spleen, thickening of bowel walls from chronic inflammation, or enlarged lymph nodes. CT scans may be used when more detail is needed. These findings support the diagnosis and help track organ damage over time.
Non-pharmacological treatments (therapies and others)
Strict infection-prevention hygiene and hand-washing:
Caregivers are taught to wash hands often, use alcohol gel, clean frequently touched surfaces, and separate the child from people with coughs, fever, or stomach bugs. These steps lower exposure to bacteria and viruses when the immune system cannot fight well. In hospitals, staff use masks, gloves, and isolation rooms when needed to reduce the risk of hospital-acquired infections.
Safe vaccination plan for family members and avoidance of live vaccines for the patient:
The child with MALT1 deficiency usually must avoid live vaccines (such as MMR, varicella, oral polio, some intranasal flu vaccines), because their immune system may not control the live virus. Instead, doctors vaccinate parents, siblings, and caregivers with inactivated vaccines to create a “protective circle,” lowering the chance that dangerous infections are brought home.
Environmental control at home (air quality, mould, smoke-free) and dental/periodontal care:
Families are advised to keep the home free from tobacco smoke, dampness, mould, and heavy dust, because these irritants weaken lungs already under stress from repeated infections. Regular dental visits, brushing, and flossing are very important, because MALT1 deficiency is linked to severe gum disease and oral infections; good oral hygiene can cut down bacterial load and reduce pain and tooth loss.
Skin care for eczema and wound protection:
Because many patients have severe eczema and fragile skin, daily moisturizing, gentle non-soap cleansers, short lukewarm baths, and cotton clothing are recommended. Scratches and skin breaks are cleaned and protected early to avoid bacterial entry. Dermatology nurses teach families how to apply emollients and bandages correctly, which can lower the risk of skin infections and improve quality of life.
Nutrition support and growth monitoring:
Dietitians help design high-energy, high-protein meal plans to support growth and healing, especially when chronic diarrhoea or poor appetite are present. Weight, height, and body mass index are checked regularly; if growth is failing, tube feeding or special formulas may be used. Good nutrition supports immune cell production, maintains muscle, and prepares the child for HSCT if planned.
Gastrointestinal care and control of chronic diarrhoea:
Children may have inflammatory bowel-like disease, abdominal pain, and chronic diarrhoea. Non-drug strategies include small frequent meals, careful rehydration, oral rehydration salts, and avoiding foods that clearly worsen symptoms. Stool charts, symptom diaries, and regular review with a gastroenterologist help prevent dehydration, weight loss, and nutrient deficiencies.
Pulmonary physiotherapy and breathing exercises:
Chronic lung disease from repeated infections can cause scarring and reduced lung function. Chest physiotherapy, postural drainage, breathing exercises, and sometimes positive-pressure devices are used to clear mucus and improve ventilation. These techniques reduce the risk of pneumonia and help the child stay more active and less breathless during daily life.
Educational, psychosocial, and mental-health support:
Living with a life-threatening rare disease is stressful for the child and family. Psychologists, social workers, and support groups help manage anxiety, low mood, and school difficulties. Clear information, written care plans, and contact with other families reduce fear and isolation, and help parents make informed decisions about HSCT and long-term follow-up.
Individual school plan and infection-aware attendance:
Teachers may adjust class size, allow distance learning during outbreaks, and provide flexible attendance rules. This reduces exposure during peak infection seasons while still supporting education and social development. Schools can keep up-to-date emergency plans (e.g., what to do if the child develops fever at school).
Genetic counselling and family screening:
Because MALT1 deficiency is usually autosomal recessive, parents may be carriers and siblings may be affected or at risk. Genetic counselling helps families understand inheritance, reproductive options, and the value of early testing for siblings. Early diagnosis allows infection-prevention measures and careful planning for HSCT before severe complications develop.
Drug treatments
There is no drug approved specifically “for MALT1 deficiency”. Doctors use medicines that are licensed for infections, immune replacement, or HSCT support and adapt them to this disease. All dosing is individualized.
Intravenous and subcutaneous immune globulin (IVIG/SCIG):
Human immune globulin products provide pooled antibodies from healthy donors, giving “passive immunity” to patients whose own antibody responses are poor. They are given every 2–4 weeks (IVIG) or more frequently (SCIG) to prevent bacterial infections of the lungs, ears, and sinuses. Common side effects include infusion-related headache, chills, or mild allergic reactions, and rare serious events like thrombosis.
Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis and bacterial prophylaxis:
TMP-SMX is widely used in immunocompromised patients to prevent Pneumocystis jirovecii pneumonia (PJP) and some bacterial infections. FDA labels describe oral dosing regimens adjusted for age, weight, and kidney function, and warn about allergic rash, bone-marrow suppression, and kidney problems. In MALT1 deficiency it is often used long-term under close blood-test monitoring.
Broad-spectrum oral and intravenous antibiotics:
Depending on culture results and infection site, doctors may choose β-lactams, cephalosporins, or other broad-spectrum agents to treat pneumonia, sepsis, or skin infections. Drug choice and dose follow standard paediatric infectious-disease guidelines, but threshold for starting IV therapy is low because these patients can deteriorate quickly. Side effects differ by class (for example, diarrhoea or allergic reactions).
Systemic antifungals (e.g., fluconazole, echinocandins) and antivirals (e.g., ganciclovir/valganciclovir):
Because MALT1 deficiency is linked to serious fungal and CMV infections, doctors use prophylactic or therapeutic antifungals and antivirals. Fluconazole or other azoles may prevent Candida; ganciclovir or valganciclovir target CMV but can cause bone-marrow suppression, so regular blood counts are needed. Choice depends on local resistance patterns and organ function.
Acyclovir/valacyclovir and RSV/other monoclonal antibodies:
Acyclovir-type drugs can prevent or treat herpes simplex and varicella-zoster infections during periods of high risk. In some high-risk infants with severe immunodeficiency, monoclonal antibodies against respiratory syncytial virus (such as nirsevimab) may be used seasonally to reduce hospitalisation from RSV, as described in FDA prescribing information for these agents.
Topical and systemic corticosteroids for eczema and inflammatory gut disease:
Low- to mid-potency topical steroids are used for short courses to calm severe eczema flares, always combined with emollients. Inflammatory bowel-like disease may sometimes require oral or IV corticosteroids or gut-targeted steroids such as budesonide. While these medicines reduce inflammation, they can further suppress immunity and must be used cautiously and time-limited.
Proton pump inhibitors and gastroprotective drugs:
Children on long-term steroids, NSAIDs, or certain transplant medicines may receive proton pump inhibitors to protect the stomach lining and reduce ulcer risk. These drugs lower acid production but can slightly increase the risk of some infections, so benefits and risks are carefully balanced in immunodeficient patients.
Haematopoietic growth factors (e.g., G-CSF) and supportive blood products:
In some situations (for example, during severe infection, chemotherapy, or HSCT), granulocyte colony-stimulating factor (G-CSF) may be given to stimulate neutrophil production. Red-cell or platelet transfusions are used if anaemia or thrombocytopenia develop. These treatments support the blood system but do not correct the underlying genetic defect.
Immunosuppressive/transplant-related drugs (e.g., calcineurin inhibitors, methotrexate, ATG):
Around HSCT, drugs such as cyclosporine, tacrolimus, methotrexate, and anti-thymocyte globulin (ATG) are used to prevent graft-versus-host disease and allow donor cells to engraft. These medicines suppress immune responses further for a time, so intensive infection prophylaxis is continued. Dosing follows established HSCT protocols in specialised centres.
Conditioning chemotherapy for HSCT (e.g., busulfan, fludarabine, cyclophosphamide) and post-transplant antimicrobials:
Before stem cells are infused, patients receive combination chemotherapy to clear diseased marrow and create “space” for donor cells. Regimens vary by centre and patient condition. After HSCT, broad antimicrobial prophylaxis and careful blood-level monitoring of transplant drugs are used to protect the patient during immune reconstitution.
Dietary molecular supplements
Supplements never replace HSCT or prescribed medicines. They should only be used if a doctor or dietitian agrees they are safe for this specific child.
-
Vitamin D:
Vitamin D supports bone health and modulates immune responses, and deficiency is common in chronically ill children. A doctor may prescribe a daily dose based on blood levels to reach the safe target range. Excess vitamin D can cause high calcium and kidney problems, so self-supplementation is not advised. -
Zinc:
Zinc is essential for wound healing and normal activity of many immune enzymes. If blood tests show low zinc, a paediatric dose may be given, usually with food to reduce stomach upset. Too much zinc can cause nausea, interfere with copper absorption, and disturb blood counts. -
Selenium:
Selenium is required for antioxidant enzymes that protect cells from oxidative damage. In deficiency, supervised supplementation may improve antioxidant defence, but doses must stay within a narrow safe window because excess selenium can be toxic and cause hair loss, nail changes, or nerve problems. -
Omega-3 fatty acids (fish oil or algae-based):
Omega-3s may help control chronic inflammation in skin and gut by shifting the balance of inflammatory mediators. Dietitians may suggest a child-appropriate dose and monitor for side effects like fishy aftertaste or, rarely, bleeding tendency at very high doses. -
Probiotics (case-by-case):
Some clinicians consider specific probiotic strains to support gut microbiome health, but in severe immunodeficiency there is a theoretical risk of probiotic bacteria causing bloodstream infection. Any probiotic use must be carefully discussed with an immunologist and gastroenterologist. -
Glutamine:
Glutamine is an amino acid used as fuel by intestinal cells and immune cells. In some critical-care settings it has been studied to support gut barrier function, but benefits and risks in primary immunodeficiency are not fully defined, so specialist advice is needed before use. -
High-protein oral nutritional supplements:
When normal food intake is low, paediatric high-energy, high-protein drinks can help reach calorie and protein goals. These products often contain balanced vitamins and minerals, but they must be chosen carefully if the child has food allergies or kidney problems. -
Folate and vitamin B12 (when deficient):
Chronic illness, poor intake, or gut inflammation may cause folate or B12 deficiency, leading to anaemia and fatigue. Replacement doses are based on blood tests; excess, unnecessary supplementation is avoided, especially if kidney or liver function is impaired. -
Iron (only with proven deficiency):
Iron is needed for red blood cell production, but giving iron to someone without deficiency can worsen infections by feeding bacteria. Doctors check ferritin and other markers before prescribing child-appropriate iron doses and monitoring for constipation or stomach upset. -
Electrolyte and micronutrient-balanced oral rehydration solutions:
Specially formulated oral rehydration solutions replace fluids, salts, and glucose during diarrhoea or vomiting episodes. They prevent dehydration and help maintain blood volume better than plain water or sugary drinks, and are an important part of home management plans.
Immune-boosting, regenerative and stem-cell–related therapies
-
Hematopoietic stem cell transplantation (HSCT) with donor stem cells:
HSCT is currently viewed as the most effective long-term treatment for MALT1 deficiency, because donor stem cells can rebuild a functional immune system. It uses conditioning chemotherapy plus infusion of matched donor cells, then careful monitoring for graft-versus-host disease and infections. Several reported cases show clinical resolution after HSCT. -
Growth factors such as G-CSF (granulocyte colony-stimulating factor):
G-CSF is sometimes used around infections or chemotherapy to increase neutrophil counts, helping the body clear bacteria and fungi. It is injected under the skin, and side effects can include bone pain or very high white-cell counts, so dosing and duration are tightly controlled. -
Erythropoiesis-stimulating agents (ESAs):
If chronic anaemia occurs due to inflammation, kidney involvement, or treatment, ESAs may be used to stimulate red blood cell production and reduce the need for transfusions. These drugs act on bone marrow and are dosed according to haemoglobin levels, with monitoring for high blood pressure or clot risk. -
Thrombopoietin receptor agonists (e.g., eltrombopag) in selected cases:
In rare situations of severe treatment-related thrombocytopenia, thrombopoietin receptor agonists may be used to boost platelet production. Because they can carry risks such as liver function changes or thrombosis, they are reserved for carefully selected patients under haematology supervision. -
Mesenchymal stromal cell infusions (research settings):
In some transplant centres, mesenchymal stromal cells are studied as a way to reduce graft-versus-host disease or help repair damaged tissues. These cell-based therapies are experimental and only available in clinical trials or highly specialised programmes. -
Future gene-targeted therapies (research only):
Scientists are exploring gene-editing or gene-addition strategies for several inborn errors of immunity. For MALT1 deficiency, this work is still in pre-clinical or very early research phases, so it is not standard care. Families may be offered participation in observational or research studies but should avoid any unregulated “stem cell” clinics.
Surgeries and procedures
-
Central venous catheter (port) placement:
A central line or port may be inserted under general anaesthesia so IV antibiotics, blood products, nutrition, or HSCT infusions can be given more safely and comfortably. The main risks are infection and clot formation, so meticulous line care is taught to families. -
Hematopoietic stem cell transplantation procedure:
Although HSCT is a medical treatment, it includes surgical and anaesthetic steps: line placement, marrow or peripheral stem cell harvesting from the donor, and infusion into the recipient. The decision to proceed involves weighing the high short-term risks against the potential cure. -
Feeding tube (gastrostomy) placement:
If oral intake is not enough to maintain growth, a gastrostomy tube can be surgically placed into the stomach. This allows safe delivery of high-calorie formulas and medicines, reduces feeding stress, and supports nutrition before and after HSCT. -
ENT and sinus surgery:
Chronic sinusitis or ear disease that does not respond to medicines may require procedures to drain fluid, remove infected tissue, or place ear tubes. These surgeries aim to improve breathing, reduce infection frequency, and protect hearing. -
Lung surgery in severe, localized damage (rare):
In very advanced cases with localized lung destruction or bronchiectasis not controlled by medicines, surgeons may consider removing severely damaged segments. This is uncommon and reserved for situations where focal disease repeatedly causes life-threatening infections.
Prevention strategies
-
Early diagnosis and genetic confirmation in at-risk siblings.
-
Regular follow-up with a specialist immunology/transplant centre, not just local clinics.
-
Written emergency plan for fever or sepsis signs, including rapid access to IV antibiotics.
-
Vaccination of close contacts with inactivated vaccines (influenza, COVID-19, pneumococcal).
-
Avoidance of live vaccines in the patient unless a specialist clearly advises otherwise.
-
Year-round hygiene, mask use during outbreaks, and avoiding crowded indoor spaces when infections are rising.
-
Aggressive dental and skin care to reduce chronic bacterial reservoirs.
-
Nutrition optimisation and prompt treatment of diarrhoea to prevent dehydration and nutrient loss.
-
Early planning and referral for HSCT when criteria are met, before irreversible organ damage occurs.
-
Education of all caregivers, teachers, and local healthcare providers about the disease and emergency steps.
When to see doctors (and when it is an emergency)
Families should keep close, routine contact with their immunology team for planned check-ups, lab monitoring, and vaccine or prophylaxis adjustments. However, urgent medical review is needed for fever, any breathing difficulty, persistent cough, chest pain, new or rapidly spreading rash, unexplained bruising or bleeding, repeated vomiting, severe diarrhoea, poor feeding, or unusual sleepiness. Emergency care is required immediately if the child has trouble breathing, bluish lips, is difficult to wake, has a seizure, or a fever that does not improve with usual measures. For post-HSCT patients, almost any fever or sudden symptom change is treated as an emergency.
What to eat and what to avoid
-
Eat: well-cooked meats, fish, and eggs (no pink or runny parts) to reduce infection risk while providing protein for growth and healing.
-
Eat: plenty of cooked vegetables, peeled fruits, and whole grains for fibre, vitamins, and minerals, adjusting texture if there is gut discomfort.
-
Eat: energy-dense snacks like yoghurt, nut butters (if no allergy), and fortified drinks if growth is behind, under dietitian guidance.
-
Eat: safe dairy or alternatives that are pasteurised to lower the risk of bacterial contamination.
-
Eat: small, frequent meals and sip oral rehydration solutions during diarrhoea to prevent dehydration.
-
Avoid: raw or undercooked meat, fish (sushi), eggs, and unpasteurised milk or cheeses, which can carry dangerous bacteria and parasites.
-
Avoid: unwashed raw fruits and salads in environments where water quality is uncertain.
-
Avoid: high-sugar drinks and junk food that provide calories without nutrients and may worsen diarrhoea or weight problems.
-
Avoid: herbal or “immune boosting” products bought online without medical review, as these may interact with medicines or be contaminated.
-
Avoid: extreme diets (very low carb, raw-only, or fad detox plans), which can worsen malnutrition and weaken the body before HSCT.
Frequently asked questions (FAQs)
-
Is MALT1 deficiency the same as “classic” severe combined immunodeficiency (SCID)?
No. MALT1 deficiency is a form of combined immunodeficiency with some overlapping features, but newborn SCID screening can be normal, and T-cell numbers may not be extremely low. Diagnosis usually requires genetic testing and detailed immune function studies. -
How is MALT1 deficiency diagnosed?
Doctors use a combination of clinical history (recurrent infections, eczema, gut disease, poor growth), immune-cell tests, and finally sequencing of the MALT1 gene. Functional studies may show defective NF-κB signalling in T-cells. Family testing can confirm inheritance patterns. -
Can my child grow out of MALT1 deficiency?
No. It is a genetic condition, so the underlying defect does not disappear with age. Supportive care may reduce infections, but without HSCT or a future gene-based cure, the immune problem remains. -
Is HSCT always necessary?
Not every patient has the same severity, but case reports and expert reviews suggest that HSCT is strongly recommended for most symptomatic children, especially when infections and inflammation are difficult to control. The final decision is made by the family and transplant team after detailed risk–benefit discussions. -
What are the main risks of HSCT in MALT1 deficiency?
Short-term risks include severe infections, organ toxicity from chemotherapy, and graft-versus-host disease. Long-term risks may include chronic GVHD, fertility issues, or secondary cancers. However, without HSCT, recurrent infections and organ damage can also be life-threatening. -
Can regular immunoglobulin and antibiotics replace HSCT?
They can reduce infections and improve quality of life, but they do not correct the basic immune signalling defect. Over years, chronic inflammation and organ damage can still occur, so supportive treatment is often seen as a bridge to HSCT rather than a complete solution. -
Will my other children be affected?
MALT1 deficiency is usually autosomal recessive, meaning each pregnancy has a 25% chance of an affected child if both parents carry one faulty copy. Genetic counselling, carrier testing, and possibly prenatal or pre-implantation testing can be discussed with specialists. -
Can adults have MALT1 deficiency?
Most cases are detected in childhood because infections and inflammation start early, but some individuals may be diagnosed later if symptoms were milder or missed. Adult diagnosis still requires genetic testing and expert immunology assessment. -
Are “immune boosters” from shops safe or helpful?
Most over-the-counter “immune boosters” have not been tested in patients with primary immunodeficiency and may interact with medicines or be contaminated. They should not be used without approval from the treating team. -
Is it safe for my child to go to school?
Many children can attend school with precautions: good hygiene, staying home when unwell, flexible attendance during outbreaks, and coordination between the medical team and school staff. Decisions are personalised based on infection history and treatment stage (for example, pre- vs post-HSCT). -
Can my child receive routine childhood vaccines?
Some inactivated vaccines may still be recommended, while live vaccines are often avoided. Vaccine plans are highly individual and must be created by the immunology team; never give live vaccines without their explicit approval. -
What about COVID-19?
Because these patients are at high risk, families are usually advised to follow strict infection-prevention measures, ensure household vaccination when appropriate, and seek early medical review if respiratory symptoms or fever appear. Specific therapies (such as monoclonal antibodies or antivirals) are chosen based on current guidelines. -
Can diet alone fix the immune problem?
No. Good nutrition supports growth and healing and is very important, but it cannot repair the genetic error in MALT1. Diet should be seen as part of overall supportive care, not a cure. -
What is the long-term outlook for a child with MALT1 deficiency?
Without effective treatment, there is a high risk of serious infections, chronic lung and gut damage, and reduced survival. However, case reports show that children who receive timely HSCT and high-quality supportive care can have major improvement and, in some cases, near-normal immune function. -
Where can families find more help and information?
National and international primary immunodeficiency organisations, rare disease registries, and specialist immunology centres provide educational materials, patient stories, and links to expert clinics. Joining these networks can help families stay updated on new research and clinical trials.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: February 13, 2025.
